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Abstract 
Objectives 
Resource allocation is a challenging issue faced by health policy decisionmakers requiring 
careful consideration of many factors. Objectives of this study were to identify decision 
criteria and their frequency reported in the literature on healthcare decisionmaking. 
Method 
An extensive literature search was performed in Medline and EMBASE to identify articles 
reporting healthcare decision criteria. Studies conducted with decisionmakers (e.g., focus 
groups, surveys, interviews), conceptual and review articles and articles describing 
multicriteria tools were included. Criteria were extracted, organized using a classification 
system derived from the EVIDEM framework and applying multicriteria decision analysis 
(MCDA) principles, and the frequency of their occurrence was measured. 
Results 
Out of 3146 records identified, 2790 were excluded. Out of 356 articles assessed for 
eligibility, 40 were included in the study. Criteria were identified from studies performed in 
several regions of the world involving decisionmakers at micro, meso and macro levels of 
decision and from studies reporting on multicriteria tools. Large variations in terminology 
used to define criteria were observed and 360 different terms were identified. These were 
assigned to 58 criteria which were classified in 9 different categories including: health 
outcomes; types of benefit; disease impact; therapeutic context; economic impact; quality of 
evidence; implementation complexity; priority, fairness and ethics; and overall context. The 
most frequently mentioned criteria were: equity/fairness (32 times), efficacy/effectiveness 
(29), stakeholder interests and pressures (28), cost-effectiveness (23), strength of evidence 
(20), safety (19), mission and mandate of health system (19), organizational requirements and 
capacity (17), patient-reported outcomes (17) and need (16). 
Conclusion 
This study highlights the importance of considering both normative and feasibility criteria for 
fair allocation of resources and optimized decisionmaking for coverage and use of healthcare 
interventions. This analysis provides a foundation to develop a questionnaire for an 
international survey of decisionmakers on criteria and their relative importance. The ultimate 
objective is to develop sound multicriteria approaches to enlighten healthcare decisionmaking 
and priority-setting. 
Keywords 
Decisionmaking, Resource allocation, Priority-setting, Criteria, Healthcare 
Review 
Introduction 
Resource allocation and priority setting are challenging issues faced by health policy 
decisionmakers requiring careful consideration of many factors, including objective (e.g., 
reason) and subjective (e.g., empathy) elements.[1] Criteria used to evaluate healthcare 
interventions and allocate resources are likely to have profound implications, especially 
regarding ethical aspects. Ethical principles of resource allocation set forth by the World 
Health Organization (WHO) include efficiency (maximizing population health), fairness 
(minimizing health differences) and utility (greatest good for the greatest number).[2] 
Consideration of these often conflicting principles requires pragmatic frameworks and the 
engagement of a broad range of stakeholders to provide accountability for reasonableness 
(A4R).[3-7] Limited resources and inequities in healthcare in both wealthy and developing 
countries underline the need to allocate optimally [8]. 
As argued by various authors [9-12], choices may not be based on rational and transparent 
processes highlighting the need for processes that take this into account. Indeed, if the 
mechanism employed to guide the distribution of resources is inequitable, the outcome is also 
likely to be. Thus, how resources are allocated by health policy decisionmakers around the 
world remains a challenging issue.[13] Priority-setting is defined as the process by which 
healthcare resources are allocated among competing programs or people.[14] In the context 
of increasing healthcare costs in many countries around the world, effective approaches to 
explicit appraisal and priority setting are becoming critical to allocate resources to healthcare 
interventions that provide the most benefit to patient health as well as contributing to 
healthcare systems’ sustainability, equity and efficiency. Indeed, elucidating decision criteria 
and how they are considered are key to establishing accountability and reasonableness of 
decisions and fulfils the A4R framework set forth by Daniels and Sabin. [6] 
Over the past decades, a number of empirical studies have explored systematic approaches to 
optimize evaluation of healthcare interventions and priority-setting. A number of tools with 
defined criteria to evaluate and rank interventions have been developed, recognizing the need 
for such approaches.[10,15-28]. As part of a larger collaborative endeavour exploring 
decision criteria, the aim of this study was to analyse the peer-reviewed literature to identify 
criteria reported in empirical studies that involved healthcare decisionmakers and in studies 
describing multicriteria tools. The specific objectives were to identify, categorize and 
estimate the frequency of decision criteria reported in the literature. This work will support 
the design of an international survey of decisionmakers on criteria and their relative 
importance as well as providing a resource for developers of multicriteria-based frameworks. 
Methods 
Search strategy and article selection 
An extensive literature search was carried out in June 2010 on Medline and EMBASE 
databases to identify articles reporting healthcare decision criteria. Because studies reporting 
criteria (or factors or principles or components) are usually not indexed with such generic 
terms and because these terms are used in many fields (e.g., diagnostic criteria), a number of 
algorithms were explored to optimize the search strategy. The optimized search strategy 
included the following keywords: “decision-making”, “priority-setting”, and “resource 
allocation”, combined with “funding”, “budget”, “cost-benefit analysis”, “cost-effectiveness 
analysis”, and “equity”. The research was limited to articles published in English, French, or 
German over the last 10 years and excluded the following types of studies: clinical trials 
(phase I to IV), editorials, letters, randomized controlled trials, case reports, and comparative 
studies. Bibliographies of relevant articles were also searched. 
Abstracts of articles thus retrieved were screened to identify appropriate inclusion and 
exclusion criteria. Studies were included if they reported a set (i.e., > 1) of decision criteria 
and were: 
• 
empirical studies conducted with healthcare decisionmakers (including field-testing of 
decisionmaking tools, focus groups, questionnaires, interviews) 
• reviews of such empirical studies, and 
• 
conceptual studies describing or proposing a set of decision criteria or a decisionmaking 
tool. 
Studies were excluded if they focused on a single criterion (e.g., cost-effectiveness only) or 
described a priority-setting exercise without explicitly identifying decision criteria. Studies 
discussing the goals and advantages of priority-setting per se without reporting specific 
criteria were also excluded. To avoid double-counting of decision criteria, only one 
publication was included if several publications from the same group described the same set 
of decision criteria. For the same reason, studies reported in review articles that we included 
in our analysis and which reported the criteria of the original studies were also excluded. 
Data extraction 
Full texts of selected articles were reviewed and data extracted into a table identifying: 1) 
first author; 2) year of publication 3) method of criteria elicitation or identification, 4) 
decisionmaking setting, 5) exact term for each criterion as reported in the publication. 
Given the variability of terms to describe conceptually similar decision criteria, a hierarchical 
classification system was developed (Figure 1). Terms referring to the same concept (e.g., 
“side-effects” and “harm”) were grouped under one criterion (e.g., Safety). Related criteria 
were grouped under categories (e.g., Health outcomes and benefits of intervention). This 
process of classification was guided by the structure of the EVIDEM framework, which 
includes an adaptable set of core and contextual criteria identified from analyses of the 
literature, of decisionmaking processes worldwide, and discussions with decisionmakers , and 
which were structured to fulfill the requirements of multicriteria decision analysis (MCDA; 
i.e., minimum overlap, mutual independence, operationalizability, completeness and 
clustering).[10,18,29]. MCDA principles were applied in the present study to define criteria 
regrouping terms referring to the same concept and to categorize criteria into a meaningful 
and intuitive architecture (clustering). 
Figure 1 Categorization of terms reported in the literature 
Descriptive statistics 
The number of times each criterion was cited in the studies retrieved was used as a proxy to 
identify the criteria perceived to be most important. Descriptive statistics were performed and 
each occurrence of a term belonging to that criterion was counted. If a study reported two 
different terms that we grouped under the same criterion, both terms were counted. For 
example, if a study reported “side effects” and “harm” as separate terms, we counted both of 
them under the criterion “Safety”. The numbers of citations for each criterion and for each 
category of criteria were analyzed. 
Results 
Identification of decision criteria from the literature review 
The literature search resulted in a total of 2903 records identified through PUBMED and 
EMBASE database searching and 243 additional records were identified through 
bibliographic hand searching (Figure 2). These studies were screened by their abstracts and 
2790 were excluded. The remaining 364 studies were assessed for eligibility on the basis of 
full text and 317 articles were excluded. A total of 40 studies were included (Table 1), all of 
which were published after 1997, and 33 studies from 2006 to 2010. The majority of studies 
reported criteria derived from interviews and focus groups (9 studies each) surveys (2) or 
literature review of studies (5) conducted with healthcare decisionmakers at micro, meso and 
macro levels of decision and from several regions of the world. Fourteen studies described 
multicriteria decisionmaking tools. 
Figure 2 PRISMA diagram 
Table 1 Studies identified in the literature and included in the analysis 
Studies reporting on decision criteria Studies describing a 
decisionmaking tool Authors Type of study and level of 
decisionmaking* 
1. Andreae et al. [9], 2009 Survey, macro 1. Bowen et al. [15], 2005 
2. Asante et al. [8], 2009 Interviews, meso & macro 2. Browman et al. [16], 2008 
3. Baltussen et al. [12], 
2007 
Focus group, macro 3. Ghaffar et al. [17], 2010 
4. Baltussen et al. [30], 
2006 
Focus group, meso & macro 4. Goetghebeur et al. [10,18], 
20008,2010 
5. Baltussen et al. [11], 
2006 
Methodology 5. Golan et al. [19], 2010 
6. Dionne et al. [31], 2009 Interviews, macro 6. Hailey et al. [20], 2009 
7. Dolan et al. [32], 2010 Methodology 7. Honore et al. [21], 2010 
8. Duthie et al. [33], 1997 Interviews, micro, meso & 
macro 
8. Johnson et al. [22], 2009 
9. Gibson et al. [34], 2006 Focus group & interviews, meso 
& macro 
9. Kirby et al. [23], 2008 
10. Hofmann et al. [35], 
2005 
Literature review 10. Meagher et al. [24], 2010 
11. Irving et al. [36], 2010 Interviews, micro 11. Menon et al. [25], 2010 
12. Jehu-Appiah et al. [37], 
2008 
Focus group, macro 12. Tannahill et al. [26], 2008 
13. Kapiriri et al. [38], 
2009 
Interviews, micro, meso & 
macro 
13. The University of York 
[27], 2002 
14. Koopmanschap et al. 
[39], 2010 
Focus group, macro 14. Wilson et al. [28], 2006 
15. Lasry et al. [14], 2010 Interviews, macro  
16. Lehoux et al. [40], 
2007 
Literature review  
17. Lopert et al. [41], 2009 Focus group, macro  
18. Martin et al. [42], 2001 Focus group, macro  
19. Mitton et al. [43], 2006 Focus group, macro  
20. Mullen et al. [44], 2004 Survey, meso  
21. Noorani et al. [45], 
2007 
Literature review and interviews, 
macro 
 
22. Saarni et al. [46], 2008 Consensus procedure, macro  
23. Vuorenkoski et al. [47], 
2008 
Literature review  
24. Wilson et al. [48], 2007 Focus group, macro  
25. Wirtz et al. [49], 2005 Interviews, macro  
26. Youngkong et al. [13], 
2009 
Literature review  
*Survey, interviews and focus groups were performed with healthcare decisionmakers 
making decisions at national or regional level (macro level), at a healthcare facility level 
(meso level) and/or at the healthcare provider level (micro level) 
Decision criteria classification and descriptive statistics 
Large variations in terminology used to define criteria were observed among the studies 
included; 360 different terms were identified (Table 2). Using the classification system 
described above, these terms were assigned to 58 unique criteria which were classified into 9 
different categories. These were: A) health outcomes and benefits of intervention (6 criteria), 
B) types of health benefit (2 criteria), C) impact of disease targeted by intervention (4 
criteria), D) therapeutic context of intervention (4 criteria), E) economic impact of 
intervention (9 criteria), F) quality/uncertainty of evidence (6 criteria), G) implementation 
complexity of intervention (9 criteria), H) priorities, fairness and ethics (7 criteria), I) Overall 
context (11 criteria). Categories were defined to: i) regroup criteria pertaining to the same 
overall concept (e.g., category “A - Health outcomes and benefits” of intervention includes 
criteria such as health benefits, life saving, efficacy, effectiveness, safety, patient-reported 
outcomes and quality of care) and to ii) disentangle criteria specific to the intervention 
(categories A to F) from criteria specific to the context (G to I). 
Table 2 Classification of terms reported in the literature 
Categories of 
classification 
system 
Criteria of 
classification system 
Terms used in articles 
A-Health 
outcomes and 
benefits of 
intervention 
Number of criteria: 6 Number of terms: 44 
A1: Health benefits: 7 
terms, cited 10 times 
A1 – health benefits[13,31,38,50], potential health 
gain[44], enhanced health outcomes[44], relative 
advantage[51], health effects[30], additional 
effects[22], incremental health gain[43] • 
A2: 
Efficacy/effectiveness: 
11 terms, cited 29 
times 
A2 – efficacy[13,47], 
efficacy/effectiveness[10,19,20,25,27,28,44,48], 
effectiveness[14,22,26,32-34,48], clinical 
benefit[19,22,24,42,47], clinical impact[45], 
clinical merit[22], relative clinical benefit in 
relation with current standards[16], determine 
relative value for degree of benefit against 
benchmarks[16], magnitude of treatment 
effect[22], response rate[43], onset and duration of 
treatment/program effect[43] • 
A3: Life saving: 4 
terms, cited 5 times 
A3 – prolongation of disease-free survival[42], 
saving life[19], life expectancy gains[13], average 
life-year benefit per patient[13,33] • 
A4: Safety: 11 terms, 
19 times 
A4 – side effects[33,41,47], unintended 
consequences[40], safety[9,22,26,31], safety and 
tolerability[10,19,20], risks[20,22], risk 
management[44], harm[42], adverse effects[32], 
inconvenience[22], risk of event[22], reduction in 
symptomatic toxicity compared with standard 
therapy[42] 
A5: PRO: 10 terms, 17 
times 
A5 – patients reported outcomes[10], quality of 
life[19,42,44,52], impact on quality of life[22,43], 
number of QALYs gained per patient[36,39], 
disability adjusted life years[13], likely impact on 
patient[16], patient preference[25], patient 
autonomy[26,35,40], relative value to patient[16], 
best for patient[38] • 
A6: Quality of care: 1 
term, 1 time 
A6 – overall gain in quality of care[44] • 
B-Type of 
health benefit 
Number of criteria: 2 Number of terms: 12 
B1: Population effect 
(prevention): 6 terms, 
11 times 
B1 – public health interest[10], population 
effects[19], prevention[19,28], prevention of ill 
health[44], social impact[13,22,33], social 
benefit[13,22,33] • 
B2: Individual effect 
(medical service): 6 
terms, 7 times 
B2 – type of medical service[10], relief/prevention 
of symptoms/complications of disease[42], health 
gain or maintenance[44], individual effects[19], 
individual impact and benefit[13,33], the 
composition of the health gain[39] • 
C-Impact of the 
disease targeted 
by intervention 
Number of criteria: 4 Number of terms: 21 
C1: Disease severity: 2 
terms, 9 times 
C1 – severity of disease[9,10,13,19,30,37,39,47], 
impact of the disease/condition on quality of 
life[43] • 
C2: Disease 
determinants: 2 terms, 
2 times 
C2 – determinants (the factors responsible for the 
persistence of the burden)[17], characteristics of 
target condition[22] • 
C3: Disease burden: 7 
terms, 13 times 
C3 – burden of disease[9,13,22,33], disease 
burden[17,25,45,48], burden of illness[22], burden 
of therapy[22], cost to treat disease[33], cost to 
prevent disease[33], national cost of the 
disease/condition to the healthcare system[43] • 
C4: Epidemiology: 10 
terms, 16 times 
C4 – prevalence[9,13], number of potential 
beneficiaries[35,37,40], indirect beneficiaries[40], 
size of population[10,19], prevalence and incidence 
of disease[23,25,43], number of residents 
benefiting[44], number of clients served[43], 
number of patients[47], social/demographics[22], 
incidence[22] • 
D-Therapeutic 
context of 
intervention 
Number of criteria: 4 Number of terms: 18 
D1: Treatment 
alternatives: 5 terms, 
13 times 
D1 – treatment alternatives[13,22], availability of 
alternatives[16,19,25,42,44,47], availability of 
effective intervention and preventable[13], 
alternatives[35,40,45], benchmark comparators[16] 
• 
D2: Need: 8 terms, 16 
times 
D2 – comparative interventions limitations (unmet 
needs)[10], need[19,22,28,38,42,44,49], clinical 
impact (need and trends)[24], emergencies and 
need[13], apparent need[14], clinical 
need[36,41,50], desirability of effects[40], meets 
patient’s basic need[38] • 
D3: Clinical guidelines 
& practices: 4 terms, 7 
times 
D3 – evidence-based guidelines[13,33,36], best 
practice[14], clinical guidelines[10,23], academic 
health center research (establishing/or using best 
practice)[24] • 
D4: Pre-existing use: 1 
term, 1 time 
D4 – pre-existing prescribing of the drug[47] • 
E-Economic 
impact of 
intervention 
Number of criteria: 9 Number of terms: 36 
E1: Cost: 3 terms, 11 
times 
E1 – cost per patient[19], 
costs[19,20,22,27,32,42,44,47,51], unit cost[22] • 
E2: Budget impact: 6 
terms, 11 times 
E2 – budget impact on health plan[10,19,25,47], 
total budget impact[30], budget impact[32,45,47], 
usage and cost implications of competing new 
drugs if approved[16], affordability[25], operating 
and start-up costs[43] • 
E3: Broad financial 
impact: 7 terms, 7 
times 
E3 – Impact on other spending[10], financial 
impact on government[13], economic impact[45], 
economics[22], national medical costs per-
year[39], cost-saving[33], national saving in costs 
of absence per year[39] • 
E4: Poverty reduction: 
1 terms, 3 times 
E4 – positive poverty reduction[13,30,37] • 
E5: Cost-effectiveness: 
5 terms, 23 times 
E5 – cost-effectiveness[9,10,13,14,17,20,22,25-
27,30,34,37,39,41,44], economic evaluations[27], 
cost and consequences[9,13,14,41], 
pharmacoeconomic analysis[23], cost utility 
expressed as cost per QALY[22] • 
E6: Value: 2 terms, 3 
times 
E6 – value for money[32,44], financial value[44] 
• 
E7: Efficiency and 
opportunity costs: 6 
terms, 10 times 
E7 – efficiency of intervention[31], 
efficiency[10,19,22,23,44], opportunity costs[10], 
opportunity costs to the population/society[16], 
best within available resources[38], 
interdependencies[50] • 
E8: Resources: 5 
terms, 6 times 
E8 – Resources[17,51], variation in rate of use[45], 
available resources[13], resources implications[50], 
volume of activity[13] • 
E9: Insurance 
premiums: 1 term, 1 
time 
E9 – Impact on health insurance premiums[9] • 
F-Quality and 
uncertainty of 
evidence 
Number of criteria: 6 Number of terms: 34 
F1: Evidence 
available: 7 terms, 9 
times 
F1 – evidence[22,42,45], proof[22], scientific 
evidence[47], current level of knowledge[17], time 
of assessment in technology development[35], 
timelines of review[45], therapy mechani •sm of 
action[23] 
F2: Strength of 
evidence: 14 terms, 20 
times 
F2 – strength of evidence[16,44], quality of 
evidence[47], quality of data and past 
decisions[47], quality of data[22], quality[26], 
validity of evidence[10,19], related degree of 
knowledge certainty[23], certainty[48], 
consistency[19,22,44], consistent[38], 
completeness and consistency of reporting 
evidence[10], openness[26,44], selection of 
studies[35,40], precision of treatment effect[22] • 
F3: Relevance of 
evidence: 5 terms, 8 
times 
F3 – relevance of evidence[10,19], 
representativeness of users (studies vs. real 
world)[35,40], level of generalization[35,40], 
effectiveness in real practice[22], evidence of 
effectiveness[44] • 
F4: Evidence 
characteristics: 5 
terms, 7 times 
F4 – normative characteristics of study[35,40], 
choice of endpoints[35,40], clinical trial data[47], 
multiple randomized trials or meta-analysis/single 
randomized trial of reasonable size/small 
randomized trial[42], phase II[53] • 
F5: Research ethics: 2 
terms, 4 times 
F5 – Research ethics[35,40], informed 
consent[26,40] • 
F6: Evidence 
requirements: 1 term, 1 
time 
F6 – Adherence to requirement of decision making 
body[10] • 
G-
Implementation 
complexity of 
intervention 
Number of criteria: 9 Number of terms: 57 
G1: Legislation: 6 
terms, 6 times 
G1 – legal arrangements[40], legislative issues[22], 
medical liability[40], human rights legislation[23], 
legal implications[45], conformity of programs[22] 
• 
G2: Organizational 
requirements and 
capacity to implement: 
15 terms, 17 times 
G2 – System requirements[25], physical 
environment [44], environment[22,26], system 
capacity[10], local capacity[17], ability to 
implement[38], implementation[22], organization’s 
structure[51], organizational burden[49], 
logistics[36], process[28], well-organized[38], 
organizational feasibility[22,25], feasibility of 
delivery[16], deliverability[48] • 
G3: Skills: 6 terms, 6 
times 
G3 – knowledge and skills[51], nature of staff[51], 
clinical education and training[44], human 
resources availability[17], recruitment and 
retention of staff[44], attracting/retaining scarce 
clinical staff[44] • 
G4: Flexibility of 
implementation: 7 
terms, 8 times 
G4 – flexibility[51], reversibility[51], 
trialiability[51], revisability[51], ability to 
evaluate[22], provision for revision/appeals[38], 
engagement[26,48] • 
G5: Characteristics of 
intervention: 6 terms, 8 
times 
G5 – characteristics of intervention[22], 
complexity of the intervention[51], components of 
technology[35], autonomy of the intervention[38], 
autonomy[17,26,46], convenience[42] • 
G6: Appropriate use: 3 
terms, 3 times 
G6 – Appropriate use of intervention[10], 
appropriateness[44], appropriate setting/level of 
service[43] • 
G7: Barriers and 
acceptability: 3 terms, 
4 times 
G7 – acceptability[22,48], responsiveness[44], 
controversial nature of proposed technology[45] • 
G8: Integration and 
system efficiencies: 9 
terms, 9 times 
G8 – system integration (best use of elements of 
healthcare system)[34], integration into local 
community[44], ease of integration[22], impact on 
other services[40], links to other services[44], 
compatibility[22], reduction of the monitoring[33], 
reduction of waiting list size[33], impact[22] • 
G9: Sustainability: 2 
terms, 4 times 
G9 – sustainability[23,24,26], longevity[19] • 
H-Priorities, Number of criteria: 7 Number of terms: 55 
fairness and 
ethics 
H1 Population 
priorities: 5 terms, 5 
times 
H1 – perspective and current priority[13], target 
and priority-setting[14], known priorities[44], 
population priority[10], coverage of selected 
conditions[13] • 
H2 : Access: 10 terms, 
17 times 
H2 – population access[10], access[19,27,47,49], 
equity of access improvement[13], access to care 
easier[31,33,34], distribution and access to 
healthcare[35,40], accessibility[22,44], equity of 
access[44], access to health system[22], 
geographical equity[43], timeliness of access[43] 
• 
H3 : Vulnerable and 
needy population: 9 
terms, 11 times 
H3 – vulnerable population[37,38], potential 
victims[40], particular social groups with high risk 
and or increased vulnerability[23], compassion for 
the vulnerable[19], particularly needy/vulnerable 
groups[44], age of targeted group[13,30], maternal 
mortality[13], quality of maternity care 
services[13], population equity[43] • 
H4: Equity, fairness 
and justice: 12 terms, 
32 times 
H4 – equity[8,13,14,19,22,25,27,40,44,46,48], 
fairness[10,14,40,44,47], health equity[23,26], 
equality[19,26,38], distributive justice[23,25], 
formal justice[23], social justice[23], 
justice[26,46], social injustice[40], addressing 
health status inequalities at a population level[44], 
human integrity and dignity[35,40], basic human 
rights[35] • 
H5 : Utility: 2 terms, 3 
times 
H5 – utility[10,26], utilitarism[25] • 
H6: Solidarity: 6 
terms, 8 times 
H6 – solidarity[19,25,26], collectivism[26], 
mutuality[26], reciprocal trust[40], diversity[26], 
cohesion[26] • 
H7: Ethics and moral 
aspects: 11 terms, 14 
times 
H7 – ethics[14,22], ethical values[22], values[22], 
values and beliefs[51], consistency with societal 
values[22], ethical implications[45], moral 
obligation to implement a technology[35,40], rule 
of rescue[25], priority to basic and necessary 
care[38], moral consequence of HTA[35,40], moral 
challenges related to certain components of 
HTA[35] • 
I-Overall Number of criteria: 11 Number of terms: 83 
context I1: Mission and 
mandate of health 
system: 13 terms, 19 
times 
I1 – Goals of healthcare[52,53], goals[21], 
beneficence[28], non-maleficience and justice[28], 
beneficience/non-maleficience[17,26,53], strategic 
fit[9,23], medical and social worth[45], 
relevance[22], present social consensus,[17,49] 
consensus regarding public funding of a 
therapy[17,53], government mandate[17], national 
standards[24], healthcare context positioning[23] 
• 
I2: Overall priorities: 6 
terms, 6 times 
I2 – national priorities[45], national or board 
priority[14], local and national priorities[8], 
international priorities[45], alignment with external 
directives[9], strategic direction[43] • 
I3: Financial 
constraints: 8 terms, 13 
times 
I3 – budget constraints[13,33,45], cost-
containment[42,49], budget level[13,19,45], social 
economical context[16], limited provincial health 
resources[17], budget implementation 
challenges[17], economic feasibility[37], reliance 
of other services/sectors(on investment)[14] • 
I4: Incentives: 4 terms, 
5 times 
I4 – financial incentives[28,45], organizational 
support[16], donor involvement[31], incentives for 
compliance[20] • 
I5: Political aspects: 5 
terms,7 times 
I5 – political pressure[13,19,45], political 
components[52], politically and legally defensible 
decisions[42], politics[37], political impact[37] • 
I6: Historical aspects: 
3 terms, 3 times 
I6 – historical components[52], past 
experiences[16], historical budgets[19] • 
I7: Cultural aspects: 7 
terms, 10 times 
I7 – culture and religious convictions[19,28,47], 
stigma[28], compatibility with values[16], 
challenge of social and values 
arrangements[28,47], conception of certain persons 
or disease[47], psychosocial implications[34], 
public preference[14] • 
I8: Innovation: 3 
terms, 3 times 
I8 – perceived benefits of change[16], 
innovativeness[37], generation or application of 
knowledge[43] • 
I9: Partnership and 
leadership: 8 terms, 9 
times 
I9 – Partnership and networking[16], 
partnerships[9], maintaining relationship[42], 
leadership[16], community development[53], 
academic commitments: research and 
education[9,23], partnership and collaboration 
across organizations[43], contribution to position 
as a learning organization[43] • 
I10: Citizen 
involvement: 3 terms, 
3 times 
I10 – citizenship[53], ownership[53], enabling 
health literacy (empowerment)[53] • 
I11: Stakeholders 
interests and pressures: 
23 terms, 28 times 
I11-Stakeholders pressure[52], advocacy[16,45], 
pressure from physician and patients groups and 
past decisions[32], clinical expert opinions[37], 
patient representative group opinions[37], power 
relations among stakeholders[28], user of the 
technology interests[47], challenge the relationship 
between patient and physician[47], professional 
prestige[28,47], clinicians excitement and 
decisions in other hospitals[32], public reaction and 
public accountability[28], HTA’s producer 
interest[28,47], company activities[32], researchers 
ethics interests[28,47], third party agents 
involved[47], recommendations made by other 
countries[13], status in other jurisdictions[49], 
current status of public funding in other 
jurisdictions[17], drugs used in other hospitals[32], 
expressed demand[14,37], patient demand[32], 
expected level of interest (patient and medical)[34], 
entitlement[28] • 
This table is reporting all the terms (338) extracted from the selected articles and tabulates 
them using the classification system developed for this study, which is based on a 
hierarchical approach clustering 58 criteria into 9 categories 
The classification system and the number of citations for each criterion are reported in Figure 
3. The ten most frequently mentioned criteria were: equity, fairness and justice (H4, 32 
citations); efficacy/effectiveness (A2, 29 citations); stakeholder interests and pressures (I11, 
28 citations); cost-effectiveness (E5, 23 citations); strength of evidence (F2, 20 citations); 
safety (A4, 19 citations); mission and mandate of health system (I1:19 citations); 
organizational requirements and capacity (G2, 17 citations); patient-reported outcomes (A5, 
17 citations); and need (D2, 16 citations). Among these 10 most frequently cited criteria, 
three criteria were from the category “A - Health benefits and outcomes of intervention”, 
highlighting the importance of this consideration in decisionmaking. The other most 
frequently cited criteria were from seven categories of criteria, indicating that the 
classification system captured critical criteria in distinct categories. 
Figure 3 Classification system and number of citations for each criterion 
At the category level (Figure 4), the number of citations was the highest for the category of 
criteria “Overall context” (106 citations); followed by “Priorities, fairness and ethics” (90 
citations); “Health outcomes and benefits of intervention” (81 citations) “Economic impact of 
intervention” (75 citations); “Implementation complexity of intervention” (65 citations) 
“Quality and uncertainty of evidence” (49 citations); “Impact of disease targeted” (40 
citations); “Therapeutic context of intervention” (37 citations); and “Type of service 
provided” (18 citations). 
Figure 4 Number of citations for each category of criteria of the classification system 
Discussion 
This literature review revealed a burgeoning number of studies examining healthcare decision 
criteria and criteria-based decisionmaking tools, especially over the last five years. Criteria 
were identified from studies performed in several regions of the world involving 
decisionmakers at micro, meso and macro levels of decision and from studies reporting on 
multicriteria tools. Increasingly, the healthcare community is aware that beyond cost-
effectiveness, other criteria must be taken explicitly into account for transparent and 
consistent healthcare decisionmaking and priority-setting.[54-56] Indeed, elucidating 
decision criteria and how they are considered are key to establishing accountability and 
reasonableness of decisions. This is necessary to fulfill the relevance condition of the 
accountability for reasonableness (A4R) framework of Daniels and Sabin, [6] which states 
that “Decisions should be made on the basis of reasons (i.e. evidence, principles, values, 
arguments) that ‘fair-minded’ stakeholders can agree are relevant under the circumstances”. 
This analysis revealed a predominance of normative criteria, that is, answering the question 
“what should be done?” This highlights the importance of considering the actual worth or 
value of healthcare interventions rather than just feasibility criteria, (“What can be done?”). 
Of the ten most frequently cited criteria, eight were normative (equity and fairness, efficacy, 
cost-effectiveness, strength of evidence, safety, mission and mandate of healthcare system, 
need, patient-reported outcomes) and two were feasibility criteria (stakeholder pressures and 
interests, organizational requirements, and capacity). This is aligned with a review of studies 
on decision criteria in developing countries [13], and points to the need to include both 
normative and feasibility criteria in decision and prioritization tools to fully reflect and 
support the decisionmaking process. 
The criterion “equity and fairness” was the most frequently reported. This may reflect that 
equity is a guiding principle in defining the values on which decisions are based. Equity is 
difficult to operationalize in decisionmaking and priority-setting processes in a pragmatic 
manner. It is a complex ethical concept that eludes precise definition and is synonymous with 
social justice and fairness.[57] It is referred to as “a fair chance for all,”[23] “equality of 
access to healthcare resources on the basis of need,”[8] “absence of systematic disparities in 
health (or in the major social determinants of health) between groups with different levels of 
underlying social advantage/disadvantage.”[58] The WHO advocates concepts of “horizontal 
equity, providing healthcare to all those who have the same health need, and vertical equity, 
providing preferentially to those with the greatest need.”[57] The difficulty of considering 
equity in a pragmatic manner points to the need to include it systematically as 
operationalizable criteria in the decision process. If not systematic, it is less likely that 
decisions will be equitable. Decisions are generally fairest when standards are predetermined, 
explicit and consistently applied.[59] Equity is embedded in consideration of disease severity 
in prioritization of healthcare interventions. Decisionmakers generally attach more value to 
interventions for severe disease than for mild disease. This is also translated in the worst-off 
principle, which relates to an independent concern for severity; “the worse off an individual 
would be without an intervention, the more highly society tends to value that 
intervention”.[60] Systematic consideration of criteria defined on the basis of population 
priorities identified by decisionmakers (e.g., more value for interventions targeted to 
vulnerable populations such as children, the elderly, those in remote areas) is another 
pragmatic way to incorporate equity into decisionmaking. Integration of ethical 
considerations in operationalizable criteria was developed for the comprehensive multicriteria 
framework EVIDEM.[61] Ethical issues are an integral part of the EUnetHTA core model to 
ensure their explicit considerations.[46] and several frameworks focusing on equity [62] and 
ethical issues [63] have recently emerged. 
Efficacy/effectiveness was the second most frequently reported criterion; as Hawkes 
discussed recently, “governments are wrestling with the issues of efficacy and fairness in 
healthcare delivery”.[64] While efficacy measures the effect of an intervention treatment 
under controlled conditions (such as during clinical trials), effectiveness provides critical 
information on outcomes actually achieved by an intervention in real life settings. Efficacy 
and effectiveness are fundamental criteria considered at the regulatory (e.g., FDA, EMA) and 
reimbursement levels for medicines in many jurisdictions.[65-67] Because decisions 
concerning interventions at policy, clinical and patient level are made with reference to a 
given context of care (usually standard of care), improvement over existing care rather than 
absolute efficacy or effectiveness provides the most informative evidence.[10] Indeed, 
decisions about usefulness of interventions are usually based on relative advantage compared 
to existing approaches.[15] Comparative effectiveness, “the comparative assessment of 
interventions in routine practice settings”[68] is meant to help answer the question “does it 
work in my context?” and is demand-driven research aimed directly at decisionmaker 
needs.[69] For new interventions, however, effectiveness data is usually not available and 
decisions are often made on the basis of efficacy data, with the uncertainty inherent in 
innovation.[67] Evidence-based decisionmaking relies on actual benefits derived from an 
intervention so mechanisms (such as defining subcriteria) outlining specifically the most 
relevant outcomes of efficacy/effectiveness in real life are critical to ensure that the 
dimensions of efficacy/effectiveness are fully captured and communicated. 
The third most commonly reported criterion refers to stakeholder interests and pressures. 
Macro-level decisions are influenced by public pressure and advocacy [13,15,38] and the 
demand for a new program is a powerful argument for decisionmakers at the political 
level.[70] In a study exploring the basis for immunization recommendations, while vaccine 
safety was reported as important or very important in making immunization 
recommendations by all countries regardless of economic status, low and lower middle 
income countries were significantly more likely than developed countries to report that public 
pressure was an important factor.[9] Because pressures from groups of stakeholders are often 
part of the context,[10] being aware of pressures and interests at stake and how they may 
affect decisionmaking and implementation is important and should be explicitly tackled using 
a framework that encourage systematic consideration of their potential implications when 
making healthcare decisions. 
Cost-effectiveness was the fourth most commonly reported criterion. Cost-effectiveness is 
frequently used in healthcare decisionmaking [65,71] but its usefulness is the subject of 
debate.[54,56] A review of 36 empirical studies reported that the influence of cost-
effectiveness was moderate at micro, meso and macro levels of decision.[55] Designed to 
incorporate several criteria of decision (e.g., cost, efficacy/effectiveness, safety, quality of 
life) into an aggregated ratio allowing comparisons of interventions, it fails to include 
important criteria such as equity and the severity of the targeted condition.[59] In addition, 
cost-effectiveness thresholds are commonly mistaken for affordability thresholds.[59] 
Beyond cost-effectiveness ratios, health economic studies generate data that are necessary to 
evaluate healthcare interventions (e.g., resource utilization and cost consequences of a new 
intervention compared to existing care). 
This study also revealed that strength of evidence is an important aspect in decisionmaking, 
highlighting the influence of evidence-based medicine. Evidence is usually sought to 
demonstrate effectiveness (“it works”), show the need for policy action (“it solves a 
problem”), guide effective implementation (“it can be done”), and clarify cost-effectiveness 
(“it provides value for money”).[15] The quality of evidence that decisionmakers use can 
only be determined when several concepts are considered, such as scientific validity, 
completeness and relevance to the decisionmaking context.[18] The strength of evidence 
builds with time as interventions are used in real life and initial decisions made in a context 
of uncertainty (e.g., randomized clinical trial data in limited populations) may be revisited as 
evidence accumulates. A common question is how much evidence is enough to make an 
evidence-based decision.[59] Beyond scientific evidence, decisionmaking also relies on 
colloquial evidence.[72] Consideration of strength and quality of the different types of 
evidence remain an important part of the appraisal of interventions. 
Safety, a critical element of policy and clinical practice, was the sixth most cited criterion. 
Safety refers to the frequency and severity of adverse events or complications arising as a 
result of using the new technology compared to an alternative.[22] Efficacy and safety are the 
main criteria in the initial evaluation of a new intervention.[70] and the risk to benefit 
equation is a critical component of clinical and regulatory decisionmaking.[67] 
A number of other criteria were identified highlighting the complexity of healthcare 
decisionmaking and the need to support this process with tools to ensure consistency, 
transparency and accountability for reasonableness. An important milestone towards that goal 
would be to harmonize terminology. Indeed, a large variety of terminology was found in the 
literature during analysis and classification of criteria. Although a systematic approach was 
used to classify terms into criteria and overarching categories using the principles of MCDA, 
such analyses are limited by the subjective interpretation of terms reported by authors. For 
example, the terms reported in published studies such as “side effects,” “unintended 
consequences,” “risks,” “harm,” or “adverse effects” were all grouped under the criterion 
“Safety.” These variations of terminology underline the difficulty of harmonizing the 
decisionmaking processes, as several authors have noted.[10,11] It calls for well-defined 
criteria to avoid confusion and ensure sound application of multicriteria approaches to 
decisionmaking.[11,73] 
Although this analysis was limited to published studies, an extensive analysis of 
decisionmaking processes from jurisdictions around the world for coverage of healthcare 
interventions was performed to define the criteria of the EVIDEM framework, which are 
included in this analysis [10,18]. In addition, the large number of terms retrieved covers 
criteria currently used in more than 25 decisionmaking processes for coverage of 
medicines.[65] 
Conclusion 
This study highlights the importance of considering both normative and feasibility criteria for 
decisionmaking and priority setting of healthcare interventions. By providing a 
comprehensive classification of decisionmaking criteria, this analysis can promote reflection 
on the value of harmonizing terminology in this field. It can also serve as a resource when 
considering which criteria to include in sound multicriteria approaches (i.e., fulfilling 
principles of completeness, lack of redundancy, mutual independence, operationalizability 
and clustering). This analysis is also used as a foundation for the development of an 
international survey on criteria expected to further expand our knowledge of real-life 
decisionmaking and advance multicriteria approaches. 
Such approaches have the potential to integrate and facilitate pragmatic operationalization of 
a large range of considerations, including ethical considerations, in a transparent and 
consistent process. They could provide a common metric for curative and preventive 
interventions to clearly define best health improvements within resource available, as recently 
advocated by Volp and colleagues.[74 They may also provide a road map to develop more 
participative decisionmaking processes by “better combining of many elements” proposed by 
Culyer.[75] 
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